{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:26:06Z","timestamp":1777332366888,"version":"3.51.4"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Central diabetes insipidus is a rare disorder characterized by a deficiency of\n                    vasopressin. The first line drug to treat this disorder is a synthetic analogue\n                    of vasopressin, desmopressin.The primary aim of this retrospective register\n                    study was to compare desmopressin dose requirements in patients with acquired\n                    and congenital DI, and secondly to assess the influence of BMI on dose\n                    requirement and risk of hyponatremia with different drug administrations. We\n                    included all patients with suspected DI attending the endocrine department at\n                    Rigshospitalet, Copenhagen, Denmark in 2022. We identified 222 patients who were\n                    included whereof 130\/222 (58.6%) were females and median age was\n                    53 years (IQR 35 to 63). The etiology included 7\/222 (3.2%)\n                    congenital and 215\/222 (96.8%) acquired. After converting nasal\n                    and sublingual doses to equivalent oral doses, the median daily dose requirement\n                    was 600\u2009\u03bcg in patients with congenital etiology compared to\n                    200\u2009\u03bcg in patients with acquired etiology (p=0.005). We\n                    found no association between BMI and desmopressin dose requirements\n                    (p=0.6). During the past 12 months, 66\/215 (30.7%) had\n                    sodium levels&lt;136\u2009mmol\/l including 20\/215\n                    (9.3%) with sodium levels&lt;131\u2009mmol\/l. No\n                    increased risk of hyponatremia was found, when nasal and oral were compared\n                    (p=0.9). Daily desmopressin dose requirements were higher in patients\n                    with congenital DI compared to patients with acquired DI. However, this result\n                    was associated with uncertainty due to the small congenital group. BMI did not\n                    influence daily dose requirements and nor did type of administration influence\n                    the risk of hyponatremia.<\/jats:p>","DOI":"10.1055\/a-2198-7207","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T22:47:03Z","timestamp":1698274023000},"page":"206-213","source":"Crossref","is-referenced-by-count":6,"title":["Desmopressin Dose Requirements in Adults with Congenital and Acquired\n                    Central Diabetes Insipidus"],"prefix":"10.1055","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9691-8467","authenticated-orcid":false,"given":"Aslak Nykj\u00e6r","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Copenhagen University\n                    Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"Andreassen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Copenhagen University\n                    Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aase Krogh","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Copenhagen University\n                    Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Krogh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zealand University Hospital Koge, Koge,\n                    Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpeds.2021.08.087","article-title":"Variability in oral desmopressin dose requirements in children with central\n                    diabetes insipidus","volume":"239","author":"N Almutlaq","year":"2021","journal-title":"J Pediatr"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000336333","article-title":"Diabetes insipidus--diagnosis and management","volume":"77","author":"N Di Iorgi","year":"2012","journal-title":"Horm Res Paediatr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1210\/clinem\/dgaa069","article-title":"Forty-one individuals with mutations in the AVP-NPII gene associated with\n                    familial neurohypophyseal diabetes insipidus","volume":"105","author":"A Garcia-Castano","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2012-1044","article-title":"Nephrogenic diabetes insipidus: essential insights into the molecular background\n                    and potential therapies for treatment","volume":"34","author":"H B Moeller","year":"2013","journal-title":"Endocr Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.beem.2016.02.007","article-title":"Diabetes insipidus: differential diagnosis and management","volume":"30","author":"G L Robertson","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41572-019-0103-2","article-title":"Diabetes insipidus","volume":"5","author":"M Christ-Crain","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref7","first-page":"1047","article-title":"Desmopressin administration in children with central diabetes insipidus: a\n                    retrospective review","volume":"26","author":"H L Ooi","year":"2013","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-022-02191-2","article-title":"Challenges and improvement needs in the care of patients with central diabetes\n                    insipidus","volume":"17","author":"H Teare","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12020-015-0637-3","article-title":"Quality of life in the patients with central diabetes insipidus assessed by\n                    Nagasaki diabetes insipidus questionnaire","volume":"51","author":"A Nozaki","year":"2016","journal-title":"Endocrine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cen.13866","article-title":"Diagnosis and management of central diabetes insipidus in adults","volume":"90","author":"A Garrahy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2021.11.JNS211260","article-title":"Identifying risk factors for postoperative diabetes insipidus in more than 2500\n                    patients undergoing transsphenoidal surgery: a single-institution\n                    experience","volume":"137","author":"R S Joshi","year":"2022","journal-title":"J Neurosurg"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"101440","DOI":"10.1016\/j.beem.2020.101440","article-title":"Central diabetes insipidus in children: Diagnosis and management","volume":"34","author":"G Patti","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1159\/000506903","article-title":"Hypophysitis (including IgG4 and immunotherapy)","volume":"110","author":"A Angelousi","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref14","first-page":"100082","article-title":"Development and evaluation of a composite dosage form containing desmopressin\n                    acetate for buccal administration","volume":"3","author":"D Kottke","year":"2021","journal-title":"Int J Pharm X"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/adc.62.7.674","article-title":"Comparison of intranasal and oral desmopressin for nocturnal enuresis","volume":"62","author":"A Fjellestad-Paulsen","year":"1987","journal-title":"Arch Dis Child"},{"key":"ref16","first-page":"754","article-title":"Peroral treatment of diabetes insipidus with a polypeptide hormone analog,\n                    desmopressin","volume":"234","author":"M Hammer","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1651-2227.1997.tb14858.x","article-title":"Oral desmopressin treatment of central diabetes insipidus in children","volume":"86","author":"E M Boulgourdjian","year":"1997","journal-title":"Acta Paediatr"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.juro.2011.02.039","article-title":"Oral lyophylizate formulation of desmopressin: superior pharmacodynamics\n                    compared to tablet due to low food interaction","volume":"185","author":"A De Guchtenaere","year":"2011","journal-title":"J Urol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/phe.09.20","article-title":"Desmopressin for the treatment of primary nocturnal enuresis","volume":"3","author":"P van Kerrebroeck","year":"2009","journal-title":"Pediatr Health"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1507\/endocrj.50.437","article-title":"Oral DDAVP is a good alternative therapy for patients with central diabetes\n                    insipidus: experience of five-year treatment","volume":"50","author":"I Fukuda","year":"2003","journal-title":"Endocr J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/EJE-14-0719","article-title":"Abnormal plasma sodium concentrations in patients treated with desmopressin for\n                    cranial diabetes insipidus: results of a long-term retrospective study","volume":"172","author":"L A Behan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/17446651.3.1.23","article-title":"Risk of diabetes insipidus after pituitary surgery","volume":"3","author":"C Woods","year":"2008","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11102-012-0453-1","article-title":"Post-operative diabetes insipidus after endoscopic transsphenoidal surgery","volume":"16","author":"M Schreckinger","year":"2013","journal-title":"Pituitary"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2198-7207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:06:51Z","timestamp":1730812011000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2198-7207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":23,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,2,28]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2198-7207","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,25]]},"published":{"date-parts":[[2023,10,25]]}}}